PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34233230-9	2021	Osimertinib combined with MET inhibition synergistically induces apoptosis in the MET-amplified EGFR mutant NSCLC cells accompanied with augmented DR4 reduction both in vitro and in vivo.	osimertinib	0-11	TNF receptor superfamily member 10a	Homo sapiens	147-150	
33664875-14	2021	Mechanistically, osimertinib induced MARCH8-mediated DR4 proteasomal degradation and suppressed MEK/ERK/AP-1-dependent DR4 transcription, resulting in DR4 downregulation.	osimertinib	17-28	TNF receptor superfamily member 10a	Homo sapiens	119-122	
33664875-10	2021	Results: EGFR inhibitors (e.g., osimertinib) decreased DR4 levels only in EGFR mutant NSCLC cells and tumors, being tightly associated with induction of apoptosis.	osimertinib	32-43	TNF receptor superfamily member 10a	Homo sapiens	55-58	
33664875-12	2021	Increased levels of DR4 were detected in cell lines with acquired osimertinib resistance and in NSCLC tissues relapsed from EGFR-targeted therapy.	osimertinib	66-77	TNF receptor superfamily member 10a	Homo sapiens	20-23	
33664875-13	2021	DR4 knockdown induced apoptosis and augmented apoptosis when combined with osimertinib in both sensitive and resistant cell lines, whereas enforced DR4 expression significantly attenuated osimertinib-induced apoptosis.	osimertinib	188-199	TNF receptor superfamily member 10a	Homo sapiens	148-151	
33664875-14	2021	Mechanistically, osimertinib induced MARCH8-mediated DR4 proteasomal degradation and suppressed MEK/ERK/AP-1-dependent DR4 transcription, resulting in DR4 downregulation.	osimertinib	17-28	TNF receptor superfamily member 10a	Homo sapiens	53-56	
33664875-14	2021	Mechanistically, osimertinib induced MARCH8-mediated DR4 proteasomal degradation and suppressed MEK/ERK/AP-1-dependent DR4 transcription, resulting in DR4 downregulation.	osimertinib	17-28	TNF receptor superfamily member 10a	Homo sapiens	119-122